An observational study in Induction of Labour, sponsored by Ferring Pharmaceuticals. Completed at 1 site in Netherlands. Open to female participants. Per ClinicalTrials.gov, last updated 2015-09-16.
Sponsored by Ferring Pharmaceuticals · Observational
The design of the study is post-marketing, observational, multi-centre and open-label. The study does not provide treatment; only patients to whom misoprostol 200 µg vaginal delivery system (VDS) is prescribed may be included. All directions for medication usage and patient monitoring are solely at the discretion of the investigator in accordance with their usual practice and must be consistent with the Dutch prescribing information of misoprostol 200 µg VDS. No other (invasive) study-related interventions or measurements are done, other than the procedures routinely performed during induction of labour. No effort is expected from the study subjects. 150 patients from 20 Dutch centres will be included.
Ferring Pharmaceuticals is the lead sponsor of 244 studies on the registry; 4 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 13 (93%) have results posted.
Counted across the registry records on this site, refreshed daily.
Academic and peripheral hospitals in the Netherlands
Exclusion Criteria:
At the discretion of the investigator in accordance with their usual practice and consistent with the Dutch prescribing information.
Drug: Misoprostol
Also known as: Misodel®
Time to vaginal delivery of the neonate in hours
Time frame: From insertion until vaginal delivery
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ferring Pharmaceuticals